NTEC - Today's Research Reports on Stocks to Watch: GW Pharmaceuticals and Intec Pharma

NEW YORK, NY / ACCESSWIRE / September 20, 2018 / GW Pharmaceuticals hit a brand new high yesterday after a report revealed that the FDA is planning to reclassify the company’s Epidiolex to be allowed for medicinal use. Shares of Intec Pharma also saw gains despite a catalyst.

RDI Initiates Coverage on:

GW Pharmaceuticals plc
https://www.rdinvesting.com/report/?ticker=GWPH

Intec Pharma Ltd.
https://www.rdinvesting.com/report/?ticker=NTEC

GW Pharmaceuticals plc shares were up almost 3% on Wednesday at the close on almost 2.5 million shares traded. The stock hit a brand new high of $166.42 as it soared yesterday along with other marijuana stocks and received a positive FDA development. Marijuana stocks have been on a rally with Tilray leading the way after the US government approved to import marijuana from Canada into the U.S. for study. It's next month that Canada is going to start allow legal recreational marijuana sales. GW's cannabidiol-based Epidiolex gained approval from the U.S. Food and Drug Administration this past June as a treatment for childhood-onset epilepsy. According to a recent report from Morgan Stanley’s David Lebowitz, the FDA has plans to reclassify the company’s Epidiolex to now be allowed for medicinal use. This new classification will make the substance more widely accepted.

Access RDI’s GW Pharmaceuticals plc Research Report at:
https://www.rdinvesting.com/report/?ticker=GWPH

Intec Pharma Ltd. shares were up a 13.16% at the close on Wednesday with colossal trading volume at over 1 million shares. The average trading volume for the stock is just under 90,000 shares. There was no news nor catalyst to explain the random jump in share price as well as trading volume boost. It was last month that the company announced financial results for the three and six months ended June 30, 2018 and provided a corporate update. The company said that global enrollment reached more than 400 of the projected 420 patients into the Phase 3 ACCORDANCE clinical trial of Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for the treatment of advanced Parkinson's disease patients. CEO Jeffrey A. Meckler, stated at the time, "We continue to be pleased with the progress Intec has made during the first half of 2018, as we made significant advances that position us to achieve a number of important clinical, commercial and corporate milestones throughout the balance of the year and beyond. We are particularly excited about the progress we've made with our Phase 3 program for AP-CD/LD as a new backbone therapy for advanced Parkinson's disease patients. As we near completion of global enrollment, we have completed planned enrollment at our sites located in Europe and Israel, leaving the balance of enrollment to our U.S. sites. We remain on track to report topline data in mid-2019.”

Access RDI’s Intec Pharma Ltd. Research Report at:
https://www.rdinvesting.com/report/?ticker=NTEC

Our Actionable Research on GW Pharmaceuticals plc (NASDAQ: GWPH) and Intec Pharma Ltd. (NASDAQ: NTEC) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com